Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Nov-24 4:15 PM View:  | Forgrowth Nap B.V. 10% Owner | Newamsterdam Pharma Co N.V. (NAMS) | 18-Nov-24 | Sale (Planned) | 33,273 | $25.08 | $834,440.00 | (< 1%) 11.81M to 11.78M | |
| 19-Nov-24 4:15 PM View: | Forgrowth Nap B.V. 10% Owner | Newamsterdam Pharma Co N.V. (NAMS) | 15-Nov-24 | Private Sale (Planned) | 8,530 | $25.02 | $213,436.00 | (< 1%) 11.82M to 11.81M | |
| 15-Nov-24 4:36 PM View: | Forgrowth Nap B.V. 10% Owner | Newamsterdam Pharma Co N.V. (NAMS) | 14-Nov-24 | Sale (Planned) | 9,832 | $25.01 | $245,856.00 | (< 1%) 11.83M to 11.82M | |
| 15-Nov-24 4:36 PM View: | Forgrowth Nap B.V. 10% Owner | Newamsterdam Pharma Co N.V. (NAMS) | 13-Nov-24 | Private Sale (Planned) | 1,066 | $25.00 | $26,654.60 | (< 1%) 11.83M to 11.83M | |
| 01-Oct-24 5:23 PM View: | Kooij Louise Frederika Chief Accounting Officer | Newamsterdam Pharma Co N.V. (NAMS) | 01-Oct-24 | Option Sale | 45,000 | $15.72 | $707,400.00 | (50%) 90.0K to 45.0K | |
| 01-Oct-24 5:23 PM View: | Kooij Louise Frederika Chief Accounting Officer | Newamsterdam Pharma Co N.V. (NAMS) | 27-Sep-24 | Option Exercise | 45,000 | -- | -- | 100% 45.0K to 90.0K | |
| 30-Sep-24 5:22 PM View: | Audet Juliette Berangere Chief Business Officer | Newamsterdam Pharma Co N.V. (NAMS) | 26-Sep-24 | Private Purchase | 1,104 | $15.70 | $17,332.80 | 100% 0 to 1.1K | |
| 22-Aug-24 4:30 PM View: | Davidson Michael H. Chief Executive Officer Director | Newamsterdam Pharma Co N.V. (NAMS) | 20-Aug-24 | Private Purchase | 5,000 | $16.27 | $81,350.00 | < 1% 813.56K to 818.56K | |
| 24-Jun-24 8:30 AM View: | Davidson Michael H. Chief Executive Officer Director | Newamsterdam Pharma Co N.V. (NAMS) | 20-Jun-24 | Private Purchase | 5,000 | $17.26 | $86,308.50 | < 1% 808.56K to 813.56K | |
| 28-Mar-24 4:30 PM View: | Topper James N Director | Newamsterdam Pharma Co N.V. (NAMS) | 26-Mar-24 | Market Purchase | 8,429 | $21.50 | $181,224.00 | < 1% 6.8M to 6.81M | (3%) |
| 27-Mar-24 4:30 PM View: | Kastelein Johannes Jacob Pi... Chief Scientific Officer Director | Newamsterdam Pharma Co N.V. (NAMS) | 26-Mar-24 | Payment of Exercise | 11,197 | $22.72 | $254,396.00 | (6%) 201.67K to 190.48K | |
| 27-Mar-24 4:30 PM View: | Kastelein Johannes Jacob Pi... Chief Scientific Officer Director | Newamsterdam Pharma Co N.V. (NAMS) | 26-Mar-24 | Option Sale | 190,476 | $21.50 | $4,095,230.00 | (100%) 190.48K to 0 | |
| 27-Mar-24 4:30 PM View: | Kastelein Johannes Jacob Pi... Chief Scientific Officer Director | Newamsterdam Pharma Co N.V. (NAMS) | 26-Mar-24 | Option Exercise | 201,673 | -- | -- | 100% 0 to 201.67K | |
| 21-Feb-24 5:00 PM View: | Lange Louis G Director | Newamsterdam Pharma Co N.V. (NAMS) | 13-Feb-24 | Market Purchase | 5,000 | $19.00 | $95,000.00 | 25% 19.88K to 24.88K | 11% |
